Consequently, antibodies and small molecules targeting IGF-1 and IGF1R have been developed and tested in pre-clinical and clinical models, showing the potential to delay tumor growth and increase sensibility to CT and RT [50,51]. The gene discussed is IGF1R; the disease is neoplasm.